Skip to content

Arvinas ARVN Increase (Decrease) in Other Receivables

Increase (Decrease) in Other Receivables at other companies

Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's increase (decrease) in other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's increase (decrease) in other receivables?
Arvinas (ARVN) reported increase (decrease) in other receivables of -$800K in Q1 2026.
What is the long-term trend for Arvinas's increase (decrease) in other receivables?
Over 2 years (2021 to 2025), Arvinas's increase (decrease) in other receivables has grown at a -11.2% compound annual growth rate (CAGR), from $3.3M to -$2.6M.